NCT05856383View on ClinicalTrials.gov

Efficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABC

RecruitingOBSERVATIONAL

Enrollment

100

Participants

Timeline

Start Date

March 16, 2022

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions

HER2-positive Advanced Breast Cancer

Interventions

DRUG

Inetetamab Combined With Pyrotinib and Vinorelbine

Inetetamab Combined With Pyrotinib and Vinorelbine

Trial Locations (1)

310022

RECRUITING

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors

lead

Zhejiang Cancer Hospital

OTHER